Notas de prensa

  • 4 de diciembre de 2006
  • 353

Amgen Responds to Reports About Use and Safety of EPOGEN and Aranesp in CKD Anemia Therapy

THOUSAND OAKS, Calif., Dec 04, 2006 (BUSINESS WIRE) -- Amgen (NASDAQ:AMGN), today posted to its corporate web site documents intended to clarify Amgen´s position on the use of EPOGEN(R) (Epoetin alfa) and Aranesp(R) (darbepoetin alfa) and to correct what the company believes are misleading and inaccurate news reports regarding the use of its drugs. Amgen´s mission is to serve patients and the company is committed to ensuring the highest standards of patient safety.

Documents supporting the following statements have been posted on the company´s web site (www.amgen.com) under the link Amgen Responds to Reports About the Use and Safety of its Products. The documents include: 1) Amgen´s Response to Reports about the Use and Safety of its Products in Anemia Therapy; 2) Amgen´s Response to the CHOIR and CREATE Clinical Trial Data; 3) Amgen´s Letter to Nephrologists and 4) an interview with the Center for Medicare & Medicaid Services (CMS) Chief Medical Officer Barry Straube that was initially published in Inside CMS.

-- EPOGEN and Aranesp are effective and safe medicines when administered according to the Food and Drug Administration (FDA) label.

Destacadas

  • Realizar ayuno intermitente es eficaz para perder peso y mejora la salud cardiovascular en personas con problemas de obesidad

    Farmanews Farmanews

    Realizar ayuno intermitente es eficaz para perder peso y mejora la salud cardiovascular en personas con problemas de obesidad

    Leer más
  • GENESIS Biomed consolidates its position as a key player in the growth of the Spanish health innovation ecosystem

    Press Office Comunication

    GENESIS Biomed consolidates its position as a key player in the growth of the Spanish health innovation ecosystem

    Leer más
  • Docentes de la Universidad Internacional de Valencia destacan la búsqueda de apoyo como elemento clave en la recuperación del bienestar tras la pérdida

    Farmanews Farmanews

    Docentes de la Universidad Internacional de Valencia destacan la búsqueda de apoyo como elemento clave en la recuperación del bienestar tras la pérdida

    Leer más

Newsletter

Suscríbete para conocer las novedades del mundo farmacéutico y sanitario.

¿Qué es?

FarmaNews pone a disposición de los medios y departamentos de comunicación, un canal para publicar notas de prensa y convocatorias del mundo sanitario y farmacéutico.

Contacto

Avda. Mare de Déu de Lourdes, 108,
08757, Corbera de Llobregat
(Barcelona), España